Immuneering-color-logo-CMYK_Resized.jpg
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024 08:00 ET | Immuneering Corporation
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Immuneering-logo (1).png
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 06, 2024 16:05 ET | Immuneering Corporation
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering-logo (1).png
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
July 31, 2024 16:05 ET | Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
Immuneering-logo (1).png
Immuneering to Present at the Jefferies Global Healthcare Conference
May 29, 2024 16:05 ET | Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering-logo (1).png
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
May 07, 2024 16:05 ET | Immuneering Corporation
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering-logo (1).png
Immuneering Recognizes Melanoma Awareness Month
May 06, 2024 16:30 ET | Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
Immuneering-logo (1).png
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
April 09, 2024 12:00 ET | Immuneering Corporation
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Immuneering-logo (1).png
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024 16:05 ET | Immuneering Corporation
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Immuneering-logo (1).png
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
March 27, 2024 08:00 ET | Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Immuneering-logo (1).png
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
March 14, 2024 07:00 ET | Immuneering Corporation
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for...